• Laboratorio Farmaceutico Erfo closed the first exercise window of its “Stock Grant ERFO 2025-2027” plan on July 30, 2026.
• All 10 beneficiaries exercised 152,955 “Diritti a Ricevere”, triggering the free allocation of 152,955 ordinary shares on a 1:1 basis.
• The shares were delivered using treasury stock, avoiding any capital increase or dilution; treasury shares fell to 427,045, or 4.74% of share capital.
• Share capital stayed at EUR 1.75 million, split into 9,000,000 ordinary shares.
• Shares allocated to the chairman-CEO are subject to a 365-day lock-up from the allocation date.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Laboratorio Farmaceutico Erfo S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20259-24-2026_TELEBORSA.pdf), on July 31, 2026, and is solely responsible for the information contained therein.